Related Experiment Video
Updated: Mar 9, 2026
04:53
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
11.4K
Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study
Marta Maia Bosca-Watts1, Xavier Cortes1, Marisa Iborra1
1Marta Maia Bosca-Watts, Inflammatory Bowel Disease Unit, Digestive Disease Department, University of Valencia, University Clinic Hospital of Valencia, 46010 Valencia, Spain.
World Journal of Gastroenterology
|January 7, 2017
Summary
This study shows golimumab is effective for ulcerative colitis (UC) patients in real-world settings. Anti-TNF treatment-naïve patients had better remission rates, and the drug proved safe during induction.
Area of Science:
- Gastroenterology
- Immunology
- Pharmacology
Background:
- Ulcerative colitis (UC) is a chronic inflammatory bowel disease.
- Effective treatment options are crucial for managing UC symptoms and improving patient outcomes.
- Golimumab, a biologic therapy, has shown promise in clinical trials for UC.
Purpose of the Study:
- To assess the real-world effectiveness of golimumab in ulcerative colitis (UC) patients.
- To identify predictors of treatment response in UC patients receiving golimumab.
- To evaluate the safety profile of golimumab during the induction phase.
Main Methods:
- An observational, prospective, multi-center study was conducted.
- UC patients treated with golimumab from September 2014 to September 2015 were included.
- Clinical activity, colonoscopies, and blood tests were assessed at baseline and week 14.
Main Results:
- 69.7% of patients achieved clinical response and were steroid-free at week 14.
- Clinical remission and response rates based on physician's global assessment were 24% and 55%, respectively.
- Anti-tumor necrosis factor (TNF) treatment-naïve patients showed a higher likelihood of achieving clinical remission.
Conclusions:
- Golimumab demonstrated short-term effectiveness in a real-world UC patient cohort.
- The drug was well-tolerated, with only mild adverse effects observed.
- Real-world data support golimumab as a safe and effective option for UC induction therapy.
More Related Videos
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
580
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
580
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
588
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
588
01:29Inflammatory Bowel Disease IV: Pharmacological Management
875
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
875
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
621
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
621
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
1.3K
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
1.3K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
675
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
675